Multicentre trials powered by XNAT for ICR
XNAT is an advanced management system for research images. It uses multiple technologies to provide researchers with the tools they need to process data and view data. The ICR has been running large multicentre imaging trials using XNAT since 2017.
List of studies using XNAT in collaboration with the ICR CTSU
[1] HALT: Targeted therapy with or without dose intensified radiotHerapy for oligo-progressive disease in oncogene-Addicted Lung Tumours
FEATURED STUDY: HALT
Targeted therapy with or without dose intensified radiotHerapy for oligo-progressive disease in oncogene-Addicted Lung Tumours
Project Lead: Fiona McDonald (Royal Marsden). HALT (NCT03256981) is a phase II, randomised multi-centre study with integrated seamless continuation to phase III trial following acceptable safety and feasibility assessment. The trial recruited patients with non-small cell lung cancer (NSCLC) with an actionable mutation responding to targeted tyrosine kinase inhibitor (TKI) therapy, but who developed oligoprogressive disease (OPD) with up to five lesions. The patients were randomised into two arms, one of which received an advanced type of radiotherapy called Sterotactic Body Radiation Therapy (SBRT) that precisely targets tumours with very high doses of radiation.
HALT showcases with our ability to connect with leading cancer hospitals, both in the UK and abroad, in order to transfer anonymised imaging data, to organise them and share them securely with a variety of users of the project.
[2] KORTUC: Randomised phase II trial testing efficacy of intra-tumoural hydrogen peroxide as a radiation sensitiser in patients with locally advanced/recurrent breast cancer. NCT03946202. Project Lead: Dr Navita Somaiah (Institute of Cancer Research and Royal Marsden) KORTUC is a multi-centre, non-blinded, randomised trial with two groups comparing radiotherapy plus or minus a novel radiation sensitiser (intra-tumoural injections of hydrogen peroxide), in patients with primary or recurrent locally advanced breast cancer requiring high dose radiotherapy for lifetime control of moderate or severe morbidities.
[3] SOPRANO: SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy. NCT05990192. Project Lead: Prof Susana Banerjee (Institute of Cancer Research and Royal Marsden). is a multi-centre, randomised phase II trial which aims to assess the impact of Stereotactic radiotherapy (SBRT) and continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.
[4] WISER-P: Real-world testing of software for measuring bone disease on whole-body MRI in patients with prostate cancer. 54072577 Project Lead: Prof Dow-Mu Koh (Royal Marsden Hospital and Institute of Cancer Research). WISER-P is a prospective, randomised, multi-centre, controlled trial comparing the clinical performance of whole-body MRI (WBMRI), used with novel software, and conventional imaging (CT & bone scan), to assess treatment response of bone disease in patients with bone predominant metastatic castration resistant prostate cancer (mCRPC).